Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Activity Up Year-Over-Year, Driven By Tax-Inversion Deals And Diversification

This article was originally published in The Pink Sheet Daily

Executive Summary

The Actavis/Forest deal was the largest deal in the first quarter, but was among 62 deals in total that were signed in the biopharma sector during the quarter.

Advertisement

Related Content

European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies
Actavis’ Big Bet On A Diversified Hybrid Model
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel